Estramustine Phosphate

Summary

Estramustine Phosphate (CHEMBL1756) is an approved small molecule; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 520.4 Da · C23H32Cl2NO6P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1756
Name	Estramustine Phosphate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	259329
ChEBI	CHEBI:68643
Molecular formula	C23H32Cl2NO6P
Molecular weight	520.4
InChIKey	ADFOJJHRTBFFOF-RBRWEJTLSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl

IUPAC name: [(8R,9S,13S,14S,17S)-13-methyl-17-phosphonooxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate

ChEBI definition: A steroid phosphate which is the 17-O-phospho derivative of estramustine.

Also known as: Estracyt, Estramustine phosphate, Ls 299, Ls-299, NSC-89199, SID144206584, ESTRAMUSTINE PHOSPHATE, Estramustine Phosphate�Na, estramustine phosphate

Parent form; salt/anhydrous children: CHEMBL1200721

Patent coverage: 43 distinct patent families (56 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 45 (80%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: D(1A) dopamine receptor, Estrogen receptor, Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2, Adenosine receptor A3, Vascular endothelial growth factor receptor 2, Tyrosine-protein phosphatase non-receptor type 6, Tyrosine-protein phosphatase non-receptor type 1, Tyrosine-protein phosphatase non-receptor type 11.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	5.69	AC50	2034	nM	CHEMBL_ACT_25138574
ADORA3	5.11	AC50	7842	nM	CHEMBL_ACT_25198490
PTPN11	5.08	Kd	8400	nM	CHEMBL_ACT_5125750

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00218205	PHASE2	UNKNOWN	A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).